Lenvatinib plus everolimus prolonged progression-free survival compared to cabozantinib in patients with metastatic clear cell renal cell carcinoma that progressed on prior PD-1 inhibition. Despite a higher incidence of severe adverse events, the treatment was effective in terms of response rate and progression-free survival.
Study
|
Randomized, open-label, multicenter phase 2 trial [LenCabo] |
| Metastatic clear cell RCC progressed on PD-1 ICI |
| Lenvatinib+Everolimus (n=40) vs Cabozantinib (n=46)
|
Efficacy
|
ORR: 52.6% vs 38.6% |
| mPFS: 15.7 mos vs 10 mos (HR 0.54 [0.32-0.93])
|
Safety
|
Grade >=3 AEs: 67.5% vs 50% |
| Serious AEs: 27.5% vs 19.6% |
| Discontinuations: 20% vs 10.9%
|
Ann Oncol. Published online October 2025.
Hahn AW, Chahoud J, Skelton WP New Reference: Lenvatinib – Everolimus for Metastatic Clear Cell RCC
http://doi.org/10.1016/j.annonc.2025.10.009
Reviewed by Ulas D. Bayraktar, MD on Nov 12, 2025
